Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

You are right Avanir is doing study in PD-LID but looks like very early stage.
It still has ways to go. Given available drugs in the market Amantidine is subpar drug with survival period 7-8 months. I wouldn't call it competitor given Eltoprazine is superior. So at the moment there is no competition but in future possibly... what you think.

I thought biotech and JPM are same event.

http://globalbiodefense.com/event/j-p-morgan-annual-healthcare-conference/